Kendra Adams R.'s most recent trade in C4 Therapeutics Inc was a trade of 130,600 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 130,600 | 130,600 | - | - | Stock Option (Right to Buy) | |
C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 87,100 | 169,676 | - | 0 | Common Stock | |
C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 4,559 | 165,117 | - | 3.2 | 14,498 | Common Stock |
C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 1,863 | 82,576 | - | 3.2 | 5,962 | Common Stock |